Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1962 1
1963 1
1966 1
1967 1
1968 1
1969 1
1970 2
1971 1
1972 1
1973 1
1974 1
1975 1
1976 3
1977 3
1979 1
1980 5
1981 6
1982 7
1983 1
1984 5
1985 2
1986 8
1987 4
1988 8
1989 5
1990 10
1991 9
1992 9
1993 10
1994 8
1995 8
1996 14
1997 13
1998 15
1999 7
2000 7
2001 19
2002 13
2003 10
2004 22
2005 21
2006 12
2007 17
2008 14
2009 11
2010 9
2011 11
2012 18
2013 13
2014 6
2015 18
2016 17
2017 6
2018 12
2019 5
2020 5
2021 4
2022 7
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 26016145

437 results

Results by year

Filters applied: . Clear all
Page 1
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.
Sieber M, Tesch H, Pfistner B, Rueffer U, Lathan B, Brosteanu O, Paulus U, Koch T, Pfreundschuh M, Loeffler M, Engert A, Josting A, Wolf J, Hasenclever D, Franklin J, Duehmke E, Georgii A, Schalk KP, Kirchner H, Doelken G, Munker R, Koch P, Herrmann R, Greil R, Anselmo AP, Diehl V. Sieber M, et al. J Clin Oncol. 2002 Jan 15;20(2):476-84. doi: 10.1200/JCO.2002.20.2.476. J Clin Oncol. 2002. PMID: 11786577 Clinical Trial.
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
Chisesi T, Bellei M, Luminari S, Montanini A, Marcheselli L, Levis A, Gobbi P, Vitolo U, Stelitano C, Pavone V, Merli F, Liberati M, Baldini L, Bordonaro R, Pesce EA, Federico M. Chisesi T, et al. J Clin Oncol. 2011 Nov 10;29(32):4227-33. doi: 10.1200/JCO.2010.30.9799. Epub 2011 Oct 11. J Clin Oncol. 2011. PMID: 21990405 Clinical Trial.
BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rueffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-Jahn U, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Duehmke E, Georgii A, Loeffler M. Diehl V, et al. J Clin Oncol. 1998 Dec;16(12):3810-21. doi: 10.1200/JCO.1998.16.12.3810. J Clin Oncol. 1998. PMID: 9850026 Clinical Trial.
Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, Ho A, Dörken B, Rank A, Grosu AL, Wiegel T, Karstens JH, Greil R, Willich N, Schmidberger H, Döhner H, Borchmann P, Müller-Hermelink HK, Müller RP, Engert A. Eich HT, et al. J Clin Oncol. 2010 Sep 20;28(27):4199-206. doi: 10.1200/JCO.2010.29.8018. Epub 2010 Aug 16. J Clin Oncol. 2010. PMID: 20713848 Clinical Trial.
ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, Liberati M, Baldini L, Deliliers GL, Angelucci E, Bordonaro R, Federico M; Intergruppo Italiano Linfomi. Gobbi PG, et al. J Clin Oncol. 2005 Dec 20;23(36):9198-207. doi: 10.1200/JCO.2005.02.907. Epub 2005 Sep 19. J Clin Oncol. 2005. PMID: 16172458 Clinical Trial.
14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M, Bredenfeld H, Josting A, Reineke T, Rueffer U, Koch T, Naumann R, Boissevain F, Koch P, Worst P, Soekler M, Eich H, Müller-Hermelink HK, Franklin J, Paulus U, Wolf J, Engert A, Diehl V; German Hodgkin's Lymphoma Study Group. Sieber M, et al. J Clin Oncol. 2003 May 1;21(9):1734-9. doi: 10.1200/JCO.2003.06.028. J Clin Oncol. 2003. PMID: 12721249 Clinical Trial.
437 results